Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine

J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1096-8. doi: 10.1136/jnnp.53.12.1096.

Abstract

Cerebrospinal fluid (CSF) S-adenosylmethionine (SAM) levels were significantly lower in severely depressed patients than in a neurological control group. The administration of SAM either intravenously or orally is associated with a significant rise of CSF SAM, indicating that it crosses the blood-brain barrier in humans. These observations provide a rational basis for the antidepressant effect of SAM, which has been confirmed in several countries. CSF SAM levels were low in a group of patients with Alzheimer's dementia suggesting a possible disturbance of methylation in such patients and the need for trials of SAM treatment.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Alzheimer Disease / cerebrospinal fluid*
  • Alzheimer Disease / drug therapy
  • Blood-Brain Barrier
  • Depressive Disorder / cerebrospinal fluid*
  • Depressive Disorder / drug therapy
  • Double-Blind Method
  • Female
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • S-Adenosylmethionine / administration & dosage
  • S-Adenosylmethionine / cerebrospinal fluid*
  • S-Adenosylmethionine / therapeutic use

Substances

  • S-Adenosylmethionine